Top brokers say Nufarm Limited is a buy

Whilst Nufarm Limited (ASX:NUF) has downgraded FY2018 earnings guidance, market watchers point to its omega-3 project and European acquisitions as providing substantial upside from current levels.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Adverse weather conditions may have negatively affected the near-term earnings outlook for listed agricultural group, Nufarm Limited (ASX: NUF), but there are strong signs the stock may be worth looking at as a longer-term play.

On Tuesday, the company downgraded its earnings forecasts due to ongoing challenging weather conditions across Australia, Europe and the United States.

Nufarm said it expected underlying earnings before interest and tax for the twelve months to 31 July 2018 to be approximately 5% above FY2017's underlying EBIT of $302.3 million. This compared to the company's previous guidance of 5% to 10% growth.

However, Nufarm appears to have a solid long-term growth outlook, with its European acquisitions and its omega-3 project promising substantial upside from current levels.

The omega-3 project is being developed through the group's subsidiary, Nuseed Pty Ltd, and should produce the world's first plant-based source of long chain omega-3 fatty acids. This will help relieve pressure on wild fish stocks, with Nufarm claiming that one hectare of its omega-3 canola has the potential to provide the omega-3 yield from 10,000 kilograms of wild caught fish.

Morgan Stanley is one broker that sees the initiative as providing material upside for the group. The broker says there is 32% potential upside to its current price target of $11.75 and remains "Overweight" on the stock.

"In our view, NUF remains undervalued at current levels, given the improvement in the base business and robust earnings growth outlook. Beyond the base business, we think the Omega3 project presents substantial incremental upside that is yet to be captured in the share price," it said in a report.

Morgans, meanwhile, points to Nufarm's acquisitions in Europe as providing a robust earnings outlook for the group in FY2019 and FY2020.

"Its acquisition of two high-margin European product portfolios will strengthen its growth profile and earnings quality and we believe, should gradually narrow its valuation discount to peers," the broker said in a report.

Nufarm announced in October 2017 that it would acquire a portfolio of crop protection products from Adama Agricultural Solutions Ltd and Syngenta Crop Protection AG and related group companies for US$490 million. The product portfolio includes over 50 crop protection formulations which are registered for use in European markets and is expected to generate revenues of approximately A$250 million; an EBITDA contribution of approximately A$95-100 million; and be mid- to high-single digit earnings per share accretive (pre-amortisation) in the first full year of ownership (FY2019), the company says.

Credit Suisse and Morgans are also positive due to Nufarm's relatively cheap valuation at current levels. Credit Suisse has Nufarm on an FY2019 P/E of 15 times, whilst Morgans has the stock trading on an FY2019 P/E of just 13.5 times.

Morgans said that Nufarm's valuation was undemanding, particularly compared to domestic chemical peers, with Orica Ltd (ASX: ORI) on 21.9 times, Incitec Pivot Ltd (ASX: IPL) on 16.6 times and DuluxGroup Limited (ASX: DLX) on 20.1 times, according to its estimates.

Most brokers also note some near-term positives for the group at its upcoming investor day on May 10.

Motley Fool contributor Gabriella Hold has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on ⏸️ Investing

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Technology Shares

Joining the revolution: How I'd invest in ASX AI shares right now

Advances in artificial intelligence (AI) could usher in a new industrial revolution. Here’s how you can invest in it.

Read more »

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »